Affimed Reports Efficacy, Safety Data From Leukemia Treatment Study

MT NewswiresDec 9 14:02 ET

Affimed Reports Phase 1 Efficacy And Safety Data For AFM28 In Relapsed/Refractory Acute Myeloid Leukemia; AFM28, A Bispecific, Tetravalent Innate Cell Engager Targeting CD123 And CD16A, Achieved A 40% Composite Complete Remission Rate At The Highest...

BenzingaDec 9 13:31 ET

Affimed to Review Clinical Data From Lung Cancer Trial on December 17

BenzingaDec 9 06:41 ET

Biggest Stock Movers Monday: SMCI, MOMO, and More

Seeking AlphaDec 9 05:00 ET

Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%

BenzingaDec 8 12:10 ET

Express News | The FDA Has Granted RMAT Designation To The Combination Therapy Of Affimed's Acimtamig And Artiva Biotherapeutic's AlloNK (AB101) For Relapsed Or Refractory Hodgkin Lymphoma

BenzingaDec 5 06:34 ET